James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why McKesson Corporation (MCK), Under Armour Inc. (UA) and Celgene Corporation (CELG) Are 3 of Today’s Worst Stocks

For owners of McKesson (MCK), Under Armour (UA) and Celgene (CELG), it's too bad the market doesn't do do-overs.

Arch Coal Restructuring Only Buys Time Before a Bigger, Inevitable End

Though it's going to live to fight another day, Arch Coal will forever be fighting for its life. Sooner or later, it's going to get a KO punch.

Why Weight Watchers International, Inc. (WTW), Valeant Pharmaceuticals Intl. Inc. (VRX) and Gap Inc. (GPS) Are 3 of Today’s Worst Stocks

The week couldn't end soon enough for Weight Watchers International, Inc. (WTW), Valeant Pharmaceuticals Intl. Inc. (VRX) and Gap Inc. (GPS).

Dow Jones Industrial Average: When SHOULD We Panic?

After six years of bullishness, it's time for the Dow Jones Industrial Average to pay the piper. The question is, how much?

No, The New FDA Dietary Guidelines Don’t Spell Doom for KO and PEP

KO and PEP were deemed most vulnerable to the FDA's latest caloric intake suggestion, but it's a standard with more bark than bite.